Stock YPH ASTELLAS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Astellas Pharma Inc. Deutsche Boerse AG

Equities

YPH

JP3942400007

Pharmaceuticals

Market Closed - Deutsche Boerse AG
Other stock markets
 03:59:34 2024-06-21 am EDT 		5-day change 1st Jan Change
8.764 EUR +3.08% Intraday chart for Astellas Pharma Inc. -1.53% -20.18%
Jun. 03 US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab MT
May. 31 U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date CI

Business Summary

Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders.

Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).

Number of employees: 14,484

Sales per Business

JPY in Million2023Weight2024Weight Delta
Pharmaceutical
100.0 %
1,518,619 100.0 % 1,603,672 100.0 % +5.60%

Sales per region

JPY in Million2023Weight2024Weight Delta
United States
41.3 %
652,441 43.0 % 663,108 41.3 % +1.63%
Established Markets
25.9 %
358,407 23.6 % 415,567 25.9 % +15.95%
Japan
16.8 %
262,303 17.3 % 270,126 16.8 % +2.98%
International
9.9 %
144,735 9.5 % 159,073 9.9 % +9.91%
Greater China
5.5 %
80,011 5.3 % 88,503 5.5 % +10.61%
Other
0.5 %
20,722 1.4 % 7,295 0.5 % -64.80%

Managers

Managers TitleAgeSince
Naoki Okamura CEO
 Chief Executive Officer 61 86-03-31
Kitamura Atsushi DFI
 Director of Finance/CFO 52 Oct. 31
Kenji Yasukawa CHM
 Chairman 64 86-03-31
Katsuyoshi Sugita CMP
 Compliance Officer - 22-09-30
Yoshitsugu Shitaka CTO
 Chief Tech/Sci/R&D Officer - -
Tadaaki Taniguchi CTO
 Chief Tech/Sci/R&D Officer - -
Tomokazu Fujisawa BRD
 Director/Board Member 65 06-08-31
Noriyuki Uematsu BRD
 Director/Board Member 64 16-05-31
Hiroko Sakai BRD
 Director/Board Member 63 83-03-31
Atsushi Kamide IRO
 Public Communications Contact - -

Members of the board

Members of the board TitleAgeSince
Kenji Yasukawa CHM
 Chairman 64 86-03-31
Naoki Okamura CEO
 Chief Executive Officer 61 86-03-31
Tatsuro Ishizuka BRD
 Director/Board Member 68 19-05-31
Eriko Sakurai BRD
 Director/Board Member 63 -
Tomokazu Fujisawa BRD
 Director/Board Member 65 06-08-31
Hiroko Sakai BRD
 Director/Board Member 63 83-03-31
Hiroo Sasaki BRD
 Director/Board Member 68 18-05-31
Hiroshi Kawabe BRD
 Director/Board Member 72 19-05-31
Mika Nakayama BRD
 Director/Board Member - -
Katsuyoshi Sugita CMP
 Compliance Officer - 22-09-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 1,809,663,075 1,788,620,803 ( 98.84 %) 16,561,000 ( 0.9151 %) 98.84 %

Shareholders

NameEquities%Valuation
BlackRock Fund Advisors
3.662 %
66,273,504 3.662 % 653 M €
Nippon Life Insurance Co.
2.851 %
51,588,000 2.851 % 508 M €
BlackRock Japan Co. Ltd.
2.478 %
44,846,700 2.478 % 442 M €
Mitsubishi UFJ Asset Management Co., Ltd.
1.581 %
28,611,000 1.581 % 282 M €
Astellas Pharma Director Incentive Plan
0.8877 %
16,065,000 0.8877 % 158 M €
BlackRock (Netherlands) BV
0.4359 %
7,887,833 0.4359 % 78 M €
BlackRock Investment Management (UK) Ltd.
0.4294 %
7,771,247 0.4294 % 77 M €
FIL Investments (Japan) Ltd.
0.3815 %
6,903,300 0.3815 % 68 M €
TOKIO MARINE HOLDINGS, INC.
0.3498 %
6,331,105 0.3498 % 62 M €
State Street Global Advisors Ltd.
0.2319 %
4,197,437 0.2319 % 41 M €
NameEquities%Valuation
LifeSci Fund Management LLC
0.002349 %
42,500 0.002349 % 418 795 €
RhumbLine Advisers LP
0.002096 %
37,924 0.002096 % 373 703 €
GAMMA Investing LLC
0.000133 %
2,400 0.000133 % 23 650 €
PNC Investments LLC
0.000017 %
307 0.000017 % 3 025 €
Operose Advisors LLC
0.000005 %
90 0.000005 % 887 €
First Horizon Advisors, Inc.
0.000002 %
37 0.000002 % 365 €

Holdings

NameEquities%Valuation
TAYSHA GENE THERAPIES, INC.
3.89%
 7,266,342 3.89% 24,923,553 $
POSEIDA THERAPEUTICS, INC.
8.59%
 8,333,333 8.59% 24,916,666 $
ASTELLAS PHARMA INC.
0.04%
 731,000 0.04% 7,203,245 $
FIBROGEN, INC.
4.99%
 4,968,367 4.99% 5,962,040 $
ONCOLYS BIOPHARMA INC.
3.47%
 727,200 3.47% 3,040,314 $

Company contact information

Astellas Pharma, Inc.

2-5-1 Nihonbashi-Honcho Chuo-Ku

103-8411, Tokyo

+81 3 3244 3000

http://www.astellas.com
address Astellas Pharma Inc.(YPH)

Group companies

NameCategory and Sector
Astellas BV
Logo Astellas BV

Astellas BV

Financial ConglomeratesFinance

Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The company is based in Leiden, Netherlands.

Financial Conglomerates

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Astellas Pharma Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,530 JPY
Average target price
1,855 JPY
Spread / Average Target
+21.30%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.63% 796B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.51% 628B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.10% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.90% 331B
ABBVIE INC. Stock AbbVie Inc.
+9.95% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.66% 244B
ROCHE HOLDING AG Stock Roche Holding AG
+3.39% 228B
NOVARTIS AG Stock Novartis AG
+10.75% 214B
AMGEN INC. Stock Amgen Inc.
+6.99% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4503 Stock
  4. YPH Stock
  5. Company Astellas Pharma Inc.